Galderma stands out as one of the few forces capable of inventing, developing and bringing to market truly innovative dermatological solutions for patient needs and consumer benefits. Our in-house R&D organization is designed to drive efficiency and serve patients, consumers and healthcare professionals in the best possible way. It serves as one integrated R&D platform with synergies across all our product categories and is dedicated to driving innovation, and leveraging our deep scientific, clinical, medical and regulatory expertise and experience.
Our strong consumer heritage and deep science foundation support our ongoing efforts to educate customers about a wide range of conditions and treatments. We are a partner of choice for academic and industrial research collaboration around the world. This gives us access to complementary perspectives and a wide range of expertise and emerging technologies.
Our clear pipeline of priorities for each of our product categories will drive future growth and reinforce our ongoing leadership in dermatology. We are also continuously assessing strategic opportunities to supplement our pipeline with truly differentiated external assets and innovation.
IINNOVATION ACROSS OUR THREE BUSINESS UNITS
In Aesthetics, we maintain sustainable growth by focusing on premium solutions that are routinely used in procedures performed by healthcare professionals. We have a strong market presence in the facial treatment of dynamic and static wrinkles, as well as the correction of asymmetries. We will continue evolving in these areas, including with new neuromodulators, dermal fillers and biostimulators.
We are developing additional offerings for skin quality treatments, which include skin glow and texture. QM-1114 is our next-generation, ready-to-use liquid formulation of botulinum toxin type A, which we are investigating in Phase 3 trials for glabellar lines and lateral canthal lines.
In Prescription Medicine, we aim to become the leader in specialty and rare dermatology, prioritizing biotechnologies for injectable and oral products. A top priority for us is the development of the investigational therapy nemolizumab for atopic dermatitis, prurigo nodularis and chronic kidney disease-associated pruritus. We are actively investigating other indications within and beyond dermatology.
Another priority is to continue our ambition to be category leader in our established franchises. Currently we are preparing to launch Twyneo (0.1% tretinoin and 3% benzoyl peroxide) cream, a novel acne treatment that combines for the first time two of the most widely used molecules in acne care. This unique combination is enabled by a patented microencapsulation technology and provides visible results in as early as two weeks, with high tolerability. Twyneo was approved by the FDA in 2021.
Additionally, we are preparing the potential launch of the investigational topical cream Epsolay (benzoyl peroxide) cream, 5%. It has the potential to be the first FDA-approved single-active benzoyl peroxide prescription drug product for the treatment of rosacea. Epsolay sets a new standard for the use of benzoyl peroxide in rosacea through an innovative and patented microencapsulation technology.
To succeed in the competitive environment of Consumer Care, we develop innovative, premium, dermatologist-recommended products. In 2021, we undertook the largest global restage in the history of our flagship brand, Cetaphil, underpinned by cleaner formulations. It included a new, clinically proven claim of efficacy in defending against the “five signs of skin sensitivity,” while preserving the brand’s signature sensorial experience.
Cetaphil is driving a continuous flow of innovative products, with the roll-out of new benefit platforms and therapeutic lines underway - including a Gentle Clear and Optimal Hydration line extension. An example of our new therapeutic lines is the Cetaphil eczema range. Developed with dermatologists, this range offers the first consumer regimen designed to treat, restore and prevent flare-ups throughout the eczema journey. We see further opportunities for the expansion of Cetaphil into sizeable adjacent segments.
Following the acquisition of Alastin Skincare, we continue developing the product range with new innovation such as the recently-launched Alastin Skincare HA immerse Serum, designed to immerse the skin with moisture at the surface while helping to amplify its natural ability to create hyaluronic acid deep within for fuller, more youthful-looking skin over time.